KBC Securities - Hyloris Pharmaceuticals (HYL) Hyloris FIRST LOOK: FY23 results show pipeline progress, eventful year ahead

Report

KBC Securities

Jacob Mekhael

Hyloris FIRST LOOK: FY23 results show pipeline progress, eventful year ahead

Hyloris reported FY23 results showcasing the company's pipeline progress and highlighting an eventful year ahead. The company had € 30.2m in cash, which it expects to provide a runway of 18-24 months. On the pipeline front, timelines were more or less reiterated and we most look forward to the results from the pivotal study for Dofetilide IV in atrial fibrillation expected in 3Q24, which could support an NDA submission soon after. In addition to the existing pipeline (18 reformulated/repurposed products and 3 generics), Hyloris continues to guide for 30 products before 2025, which means 2024 is expected to be an eventful year with respect to new product announcements. We reiterate our BUY rating and € 19.5 TP.

14/03/2024 1 EN

Underlying

Hyloris Pharmaceuticals

See profile

BE0974363955 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Jacob Mekhael

Other Reports on these Companies

KBC Securities

Morning Notes : HYL BB

: HYL BB

May 13, 2024 May 13, 2024 1 EN

KBC Securities

Morning Notes : AED BB, DSFIR NA, HYL BB, IBAB BB, INGA NA, TESB BB, BTLS BB

: AED BB, DSFIR NA, HYL BB, IBAB BB, INGA NA, TESB BB, BTLS BB

May 2, 2024 May 2, 2024 1 EN

Degroof Petercam

Hyloris Pharma - Shares suspended pending 2023 audit and forensic review of Qliniq transaction

KPMG informed the Audit committee that additional work is required to finalize the 2023 audit. They initiated a forensic independent review regarding the Qliniq transaction, including internal communication and documentation practices. Pending the review, shares will remain suspended.The Company does not expect to change the restated accounting treatment related to the Qliniq transactions.TP and BUY rating reiterated as we believe the current share price is not fully reflective of the pipeline potential. We expect the share price to be fueled by a mixture of pipeline, clinical, & commercial ac...

May 2, 2024 May 2, 2024 1 EN

Wind Energy : A deep-dive into the wind sector The wind is changing, is your portfolio keeping pace?

In a new note focusing on Wind Energy, we aim to provide a broad insight into the value chain, the risks associated with it and the positioning of the companies in the sector. The current market environment presents both opportunities and challenges for wind energy companies. The sector has faced multiple headwinds in the past, such as inflation, rising interest rates and supply chain issues, which resulted in a substantial decline in the stock prices of wind companies. However, there's a lot of upside potential driven by the growth in the sector. This is mainly caused by the Net Zero Energy...

May 20, 2024 May 20, 2024 1 EN

Guy Sips

Guy Sips

Jensen-Group FIRST LOOK : A good start to 2024

Jensen-Group 1Q24 revenues were up y/y 11.6% to € 109.1m. The 1Q24 order intake increased y/y 34.4% to €114.9m. As a result Jensen-Group called this “a good start to 2024”. 1Q24 EBIT came in at € 11.2m (€ 11.4m in 1Q23) resulting in 10.3% 1Q24 EBIT-margin (11.7% in 1Q23). 1Q24 net result amounted to € 11.1m (€ 1.15 EPS). We maintain for the moment our Accumulate rating and € 40 Target Price as these numbers are ahead of our FY24 forecasts of 8.8% FY24E sales growth and 9.5% FY24E EBIT-margin. We will update our model after visiting this week a Jensen-Group client.

May 20, 2024 May 20, 2024 1 EN

Jacob Mekhael

Jacob Mekhael

Autolus 1Q24 update reiterates pipeline timelines, obe-cel data at ASCO

Autolus reported uneventful 1Q24 results, with a cash position of $758.5m (FY23: $ 239.6m), sufficient to fund the company into the first pivotal data from obe-cel (CD19 CAR-T) in autoimmune disease (we expect this to come in 2027/2028). The company reiterated pipeline timelines, with the next key event being additional analysis and longer follow up from the phase 2 (FELIX) trial of obe-cel in r/r adult ALL, expected at ASCO in June 2024, which will provide more insight into long term durability. We reiterate our $ 11 TP and BUY rating. Autolus is one of our life sciences top picks.

May 17, 2024 May 17, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Hyloris FIRST LOOK: FY23 results show pipeline progress, eventful year ahead

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Notes : HYL BB

Morning Notes : AED BB, DSFIR NA, HYL BB, IBAB BB, INGA NA, TESB BB, BTLS BB

Hyloris Pharma - Shares suspended pending 2023 audit and forensic review of Qliniq transaction

Wind Energy : A deep-dive into the wind sector The wind is changing, is your portfolio keeping pace?

Jensen-Group FIRST LOOK : A good start to 2024

Autolus 1Q24 update reiterates pipeline timelines, obe-cel data at ASCO

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe